Navigation Links
Should doctors tell patients about expensive, unfunded drugs?

It is unethical and paternalistic for doctors to withhold information from patients about new drugs that are not yet publicly funded, say researchers in this week's BMJ.

New drugs may be more effective than existing treatments, but many are very expensive and may not be available through publicly funded health schemes.

This raises several ethical dilemmas for doctors. Is it reasonable to ask a patient to finance the full cost of their treatment when it is not provided by government? Would it be unethical to raise the option of treatment with an unsubsidised drug?

Researchers surveyed 184 Australian cancer specialists about their opinions and practices regarding potentially useful but unsubsidised drugs.

A large proportion said they would not discuss an expensive drug with a patient if it were not subsidised because of potential psychological and emotional effects that these discussions might have on patients and their families. The survey also found that these discussions were stressful for clinicians.

But the authors argue that this practice fails to respect autonomy and may not be in the patient's best interests. They believe that withholding information on the basis of what a patient would want is "a dangerous medical path to unjustified paternalism."

A further ethical issue concerns the cost of publicly funding newer, expensive treatments, they write. This is an urgent question of distributing limited resources fairly that faces not just new drugs, but many forms of modern technological care. "The gap between what we can do and what we can afford will continue to grow, at a personal and community level."

The issue of accessing new expensive drugs has no easy solution, they say. Nevertheless, it seems unreasonable to withhold information from a patient about any potentially beneficial treatment because of concerns about capacity to pay, even if these discussions cause distress for some patients.

Society at large should discuss whether new, high-cost drugs should be publicly funded, they conclude.


'"/>

Source:BMJ-British Medical Journal


Related biology news :

1. Survey reveals women and doctors arent talking about HPV
2. Efficiency, not more doctors, is the prescription for aging population
3. Stanford doctors advance in bid to turn mice stem cells into blood vessels
4. Patients and their doctors have different perceptions about HIV and its treatment
5. Free drug samples influence prescribing, say one in three doctors
6. Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates
7. Genes and biomarkers that allow doctors to choose the right therapy for the right patient
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. Potential Cure for Lymphoma in HIV patients
10. Ophthalmologists implant five patients with artificial silicon retina microchip
11. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... 27, 2017 , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, ... LHON is a rare devastating genetic disease that leads to a sudden and rapid ... of 20 patients carrying 11778, 14484 and 3460 mutations and having experienced the onset ...
(Date:4/27/2017)... Orleans, La. (PRWEB) , ... ... ... Monitoring Technologies today announced a comprehensive rebrand and a name change to ... for the industrial and laboratory monitoring of polymer and biopharmaceutical manufacturing processes ...
(Date:4/26/2017)... ... 26, 2017 , ... Looking for gift ideas for mom ... offers one-of-a-kind gifts, ranging from gourmet cooking experiences to Farmer’s Market Tours and ... inspired with new cooking tips and techniques, thanks to Chef Jodi Abel’s expertise ...
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps ... and North America this May on the following dates: , ?    London, ... Taylor, Chairman of the Learning and Performance Institute will be the opening ...
Breaking Biology Technology: